Medscape5d
Investigative Treatments for Moderate to Severe Psoriasis Reviewed
Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...
ophthalmologytimes7d
Tyrosine kinase inhibitor: An alternative treatment for non–small-cell lung cancer metastasis to the choroid
Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...
FierceBiotech4d
Inhibikase hits pause on Parkinson's program over efficacy as it prioritizes lung drug
Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...
StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)
Equities researchers at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the stock ...
American Association of Individual Investors4d
Why Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Down 31.43%
Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 31.43%, which has investors questioning if this is right time ...
The Pharma Letter7d
Keytruda and Lenvima trial fails to show OS benefit
Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...
biopharma-reporter4d
Inhibikase to pause development of Parkinson’s drug
Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...